Hims & Hers Health is betting that the cash-pay market for weight-loss drugs will drive up customer demand although some ...

“With the semaglutide shortage declared over, Hims now has to transition its model to generate growth from other products ...

(Reuters) -Hims & Hers Health (HIMS) is betting that the cash-pay market for weight-loss drugs will drive up customer demand although some analysts see a need for the online website to adjust to ...

Cigna Healthcare, the health benefits division of the Cigna Group, has released a set of digital tools aimed at improving the ...

Long Islanders, doctors and industry experts weigh in on medicines like Ozempic and Wegovy — how they work, what they ...

These companies own 97% of the weight loss drug market -- which could grow tenfold over the next decade -- and are developing next-generation offerings.

Weight-loss drugs are already dropping in price; could they go even lower? - Consumers are now able to pay roughly $500 for the drugs, which often retail at more than $1,000 ...

Chugai plans to pair its muscle-preserving drug with Eli Lilly's orforglipron, addressing muscle loss in obesity care as the ...

On Friday, May 23, UBS analyst AJ Rice reaffirmed a “Buy” rating on The Cigna Group (NYSE:CI) with a price target of ... out-of-pocket expenses for weight-loss drugs Zepbound and Wegovy ...

Diabetes care startup Omada Health went public Friday 14 years after its founding. Here's what its major investors' stakes ...

The team at Omada Health took a victory lap Friday after the company's successful Nasdaq debut, according to company President Wei-Li Shao. | The team at Omada Health took a victory lap Friday after ...